"Shock waves" from GSK's $750M settlement on alleged cGMP failures, lawyers say

GlaxoSmithKline's recent agreement to pay $750 million to resolve civil and criminal liability in connection with alleged cGMP failures at its now-shuttered facility in Cidra, Puerto Rico, is outside the norm and some believe opens up a new frontier for US whistleblower suits.

GlaxoSmithKline's recent agreement to pay $750 million to resolve civil and criminal liability in connection with alleged cGMP failures at its now-shuttered facility in Cidra, Puerto Rico, is outside the norm and some believe opens up a new frontier for US whistleblower suits.

It is undoubtedly sending "shock waves" throughout the industry and means that any FDA-regulated firm "must pay close attention to...

More from Archive

More from Scrip

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.